News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Welichem Biotech Inc. (WBI.V) Successfully Moves to Higher Dose for Phase I Clinical Trials


9/10/2007 3:03:38 PM

BURNABY, BC, Sept. 7 /CNW/ - Welichem Biotech Inc. ("WBI" or the "Company") (TSX-V: WBI - News) is very pleased to report that the Phase I Clinical Trials of the Company's anti-psoriasis drug candidate, WBI-1001, are running as planned in Montreal, Quebec. The trials consist of six separate cohorts. All six patients in Cohort I have been treated with WBI-1001 for at least fourteen days and none has experienced any adverse side effects. Patients for Cohor

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES